Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The ...

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted ...

Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed ...

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted ...

MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...

Merck (MRK) stock sank like a stone on Tuesday after the pharmaceutical giant posted poor guidance for the rest of the year.

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results , with sales up 6.8% year on year to $15.62 billion ...

Higher sales of blockbuster cancer drug Keytruda weigh against a 17% slump in sales of HPV vaccine Gardasil Merck's stock ...